These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38702918)

  • 21. Novel Oral CGRP Receptor Antagonist Atogepant in the Prevention of Migraine.
    Chowdhury S; Dave T
    Discoveries (Craiova); 2023; 11(2):e167. PubMed ID: 37564925
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of rifampicin (rifampin) on the pharmacokinetics and safety of ambrisentan in healthy subjects: a single-sequence, open-label study.
    Harrison B; Magee MH; Mandagere A; Walker G; Dufton C; Henderson LS; Boinpally R
    Clin Drug Investig; 2010; 30(12):875-885. PubMed ID: 20923245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atogepant for the Prevention of Episodic Migraine in Adults: A Systematic Review and Meta-Analysis of Efficacy and Safety.
    Lattanzi S; Trinka E; Altamura C; Del Giovane C; Silvestrini M; Brigo F; Vernieri F
    Neurol Ther; 2022 Sep; 11(3):1235-1252. PubMed ID: 35705886
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.
    Zurth C; Koskinen M; Fricke R; Prien O; Korjamo T; Graudenz K; Denner K; Bairlein M; von Bühler CJ; Wilkinson G; Gieschen H
    Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):747-759. PubMed ID: 31571146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Effect of Single and Multiple Doses of Rifampin on the Pharmacokinetics of Doravirine in Healthy Subjects.
    Yee KL; Khalilieh SG; Sanchez RI; Liu R; Anderson MS; Manthos H; Judge T; Brejda J; Butterton JR
    Clin Drug Investig; 2017 Jul; 37(7):659-667. PubMed ID: 28353169
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atogepant for the prevention of episodic migraine in adults.
    Switzer MP; Robinson JE; Joyner KR; Morgan KW
    SAGE Open Med; 2022; 10():20503121221128688. PubMed ID: 36226229
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Phase I, Open-Label, Fixed Sequence Study to Investigate the Effect of Cytochrome P450 2D6 Inhibition on the Pharmacokinetics of Ulotaront in Healthy Subjects.
    Tsukada H; Chen YL; Xiao G; Lennek L; Milanovic SM; Worden M; Polhamus DG; Chiu YY; Hopkins SC; Galluppi GR
    Clin Pharmacokinet; 2023 Dec; 62(12):1755-1763. PubMed ID: 37882999
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacologic characterization of atogepant: A potent and selective calcitonin gene-related peptide receptor antagonist.
    Moore E; Bell IM; Fraley ME; Burgey CS; White RB; Li CC; Regan CP; Danziger A; McGaraughty SP; Naseri Kouzehgarani G; Salvatore C; Banerjee P
    Cephalalgia; 2024 Jan; 44(1):3331024231226186. PubMed ID: 38215228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atogepant: an emerging treatment for migraine.
    Rustichelli C; Avallone R; Ferrari A
    Expert Opin Pharmacother; 2022 Apr; 23(6):653-662. PubMed ID: 35319319
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adults: A Randomized, Open-Label, Drug-Drug Interaction Study.
    Poggesi I; Li LY; Jiao J; Hellemans P; Rasschaert F; de Zwart L; Snoeys J; De Meulder M; Mamidi RNVS; Ouellet D
    Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):101-111. PubMed ID: 31673875
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rates of Response to Atogepant for Migraine Prophylaxis Among Adults: A Secondary Analysis of a Randomized Clinical Trial.
    Lipton RB; Pozo-Rosich P; Blumenfeld AM; Dodick DW; McAllister P; Li Y; Lu K; Dabruzzo B; Miceli R; Severt L; Finnegan M; Trugman JM
    JAMA Netw Open; 2022 Jun; 5(6):e2215499. PubMed ID: 35675076
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atogepant for the Preventive Treatment of Migraine.
    Ailani J; Lipton RB; Goadsby PJ; Guo H; Miceli R; Severt L; Finnegan M; Trugman JM;
    N Engl J Med; 2021 Aug; 385(8):695-706. PubMed ID: 34407343
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial.
    Lipton RB; Pozo-Rosich P; Blumenfeld AM; Li Y; Severt L; Stokes JT; Creutz L; Gandhi P; Dodick D
    Neurology; 2023 Feb; 100(8):e764-e777. PubMed ID: 36396451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Pozo-Rosich P; Ailani J; Ashina M; Goadsby PJ; Lipton RB; Reuter U; Guo H; Schwefel B; Lu K; Boinpally R; Miceli R; De Abreu Ferreira R; McCusker E; Yu SY; Severt L; Finnegan M; Trugman JM
    Lancet; 2023 Sep; 402(10404):775-785. PubMed ID: 37516125
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Small molecule CGRP receptor antagonists for the preventive treatment of migraine: A review.
    Dos Santos JBR; da Silva MRR
    Eur J Pharmacol; 2022 May; 922():174902. PubMed ID: 35358493
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Physiologically Based Pharmacokinetic Modeling to Assess the Impact of CYP2D6-Mediated Drug-Drug Interactions on Tramadol and O-Desmethyltramadol Exposures via Allosteric and Competitive Inhibition.
    Long T; Cristofoletti R; Cicali B; Michaud V; Dow P; Turgeon J; Schmidt S
    J Clin Pharmacol; 2022 Jan; 62(1):76-86. PubMed ID: 34383318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of a Fixed-Dose Co-Formulation of Daclatasvir, Asunaprevir, and Beclabuvir on the Pharmacokinetics of a Cocktail of Cytochrome P450 and Drug Transporter Substrates in Healthy Subjects.
    Garimella T; Tao X; Sims K; Chang YT; Rana J; Myers E; Wind-Rotolo M; Bhatnagar R; Eley T; LaCreta F; AbuTarif M
    Drugs R D; 2018 Mar; 18(1):55-65. PubMed ID: 29255971
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
    Swaisland HC; Ranson M; Smith RP; Leadbetter J; Laight A; McKillop D; Wild MJ
    Clin Pharmacokinet; 2005; 44(10):1067-81. PubMed ID: 16176119
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans.
    Jakate A; Boinpally R; Butler M; Lu K; McGeeney D; Periclou A
    Headache; 2020 Jul; 60(7):1340-1350. PubMed ID: 32573795
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patient-reported migraine-specific quality of life, activity impairment and headache impact with once-daily atogepant for preventive treatment of migraine in a randomized, 52-week trial.
    Lipton RB; Halker Singh RB; Mechtler L; McVige J; Ma J; Yu SY; Stokes J; Dabruzzo B; Gandhi P; Ashina M
    Cephalalgia; 2023 Aug; 51(8):3331024231190296. PubMed ID: 37638400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.